Patient Total / McDermott / Vysis ALK Break Apart FISH Probe Kit / Pfizer Australia Pty Ltd / Abbott Molecular Diagnostics / Abbott Australasia Pty Ltd / /
Country
Australia / /
Currency
pence / USD / /
Facility
harbor EML4-ALK / Australian Institute of Health / Cancer Institute NSW / Mayo Clinic / Royal College of Pathologists / /
IndustryTerm
transportation / clinical algorithms / pharmaceutical agent crizotinib / draft protocol / final protocol / in-vitro diagnostic medical device / therapy for non-small cell lung cancer / imaging / score algorithm / health insurer / healthcare resources / draft decision analytic protocol / /
MedicalCondition
advanced lung cancer / anaplastic lymphoma kinase inhibitors / squamous carcinomas / metastatic disease / small-cell lung cancer / metastatic non-small cell lung cancer / non-small-cell lung cancer / non-small cell lung cancer / advanced non-small cell lung cancer / Lung Adenocarcinoma / lung cancers / non-small cell lung carcinoma / Squamous cell carcinoma / Anaplastic lymphoma kinase inhibition / cancer / tumors / disease / NSCLC / primary lung cancer / IV disease / surgically resected tumours / adenocarcinoma histology / tumour / lung cancer / additional lung cancer / anaplastic lymphoma kinase / /
MedicalTreatment
combination chemotherapy / /
Organization
Royal College of Pathologists of Australasia / Lung Cancer / National Health and Medical Research Council / National Association of Testing Authorities / Australian Institute of Health and Welfare / Department of Health / Medical Services Advisory Committee / /
1250 Consultation Decision Analytic Protocol (DAP) to guide the assessment of diagnostic testing for Anaplastic Lymphoma Kinase (ALK) gene rearrangement in patients with advanced non-small cell lung cancer to determine e